SCHEMBL13099461

SCHEMBL13099461

CCc1cccc(-c2ccc(OC)c(F)c2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP17A1 P05093 1/20 0.52
▸ MGLL Q99685 4/20 0.51
▸ BCL2 P10415 1/20 0.46
▸ CD274 Q9NZQ7 1/20 0.46
▸ FFAR1 O14842 4/20 0.45
▸ PPARD Q03181 4/20 0.45
▸ PDGFRB P09619 1/20 0.44
▸ PDGFRA P16234 1/20 0.44
▸ ERN1 O75460 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ HPGD P15428 1/20 0.43
▸ PAX8 Q06710 1/20 0.43
▸ PTGS2 P35354 2/20 0.43
▸ PTGS1 P23219 1/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ IDO1 P14902 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9287916 0.85 BCL2 (0.50) BCL2ALDH1A1HPGDPTGS2MEN1
SCHEMBL14449509 0.85 CYP17A1 (0.65) CYP17A1MGLLFFAR1PDGFRBPDGFRA
SCHEMBL3163046 0.81 CYP17A1 (0.57) CYP17A1MGLLFFAR1PPARDPDGFRB
SCHEMBL25914755 0.81 BCL2 (0.53) CYP17A1BCL2PTGS2IDO1
SCHEMBL2759522 0.81 HTT (0.51) CYP17A1ALDH1A1PTGS2NPC1RAB9A
SCHEMBL18015828 0.81 BCL2 (0.46) BCL2ERN1ALDH1A1PTGS2PTGS1
SCHEMBL9464193 0.80 CYP17A1 (0.61) CYP17A1MGLLPDGFRBPDGFRAERN1
SCHEMBL8481713 0.79 CYP17A1 (0.57) CYP17A1MGLLFFAR1PDGFRBPDGFRA
Ammonia Solution, Strong SCHEMBL23291273 0.79 HTT (0.50) CYP17A1ALDH1A1PTGS2NPC1RAB9A
SCHEMBL8264634 0.78 CD274 (0.49) CYP17A1MGLLCD274PDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243333-A1 SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS UNIVERSITY OF KANSAS (US) 2014-08-28 — — US disclosed
US-20140243333-A1 SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS UNIVERSITY OF KANSAS (US) 2014-08-28 — — US disclosed
US-8735391-B2 Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods UNIVERSITY OF KANSAS (US) 2014-05-27 — — US disclosed
US-8735391-B2 Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods UNIVERSITY OF KANSAS (US) 2014-05-27 — — US disclosed
US-20100256142-A1 SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8- CARBOXAMIDES, OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS UNIVERSITY OF NORTH CAROLINA 2010-10-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256142-A1 SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8- CARBOXAMIDES, OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS OPRM1, OPRK1, OPRL1 CYP17A1 414/4885MGLL 3406/4885BCL2 4503/4885
US-20140243333-A1 SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS OPRM1, OPRK1, OPRD1 CYP17A1 159/4885MGLL 3307/4885BCL2 4490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback